Key Takeaways
- Shares of Sigma Healthcare (SIG) declined by as much as 5.5% to A$2.76 following disclosure of early-stage acquisition talks for Boots
- The potential transaction could exceed $10 billion in value, with Sigma facing competition from Canada’s Weston family
- Private equity firm Sycamore Partners, which owns Boots, is evaluating strategic options for the UK pharmacy retailer operating 1,800+ stores
- A completed transaction would terminate Boots’ previously announced London stock exchange listing plans
- Sigma has already established UK market presence through a strategic alliance with Greenlight Healthcare to launch Chemist Warehouse locations in London
Shares of Australian pharmacy operator Sigma Healthcare (SIG) tumbled as much as 5.5% to A$2.76 on Wednesday following the company’s disclosure that it has initiated exploratory talks regarding a potential acquisition of British pharmacy retailer Boots.
Sigma Healthcare Limited, SIG.AX
In a filing with the Australian Securities Exchange, Sigma acknowledged it had “engaged in preliminary discussions in relation to the sale process.” However, the company emphasized that “there is no certainty that any transaction will eventuate.”
The potential acquisition, initially disclosed by the Financial Times, could see Boots valued at more than $10 billion. Sigma isn’t alone in pursuing the opportunity — the Weston family from Canada, which controls grocery and pharmacy giant Loblaw, has also reportedly expressed interest.
Boots currently operates under the ownership of US-based private equity firm Sycamore Partners. The pharmacy chain maintains more than 1,800 locations throughout the United Kingdom and has expanded operations to 11 countries, including Ireland, Mexico, and Thailand, with a combined retail footprint of 3,776 stores as of August last year.
According to the Financial Times, successfully completing a sale would halt Boots’ previously planned initial public offering on the London Stock Exchange.
Sigma’s pursuit of Boots aligns with the company’s strategic expansion into global markets. In recent months, the Australian pharmacy group announced a collaboration with UK-based pharmacy operator Greenlight Healthcare to establish Chemist Warehouse-branded retail locations throughout London while providing operational support to Greenlight’s existing 22 stores through supply chain and promotional services.
Chemist Warehouse Financial Backing
Sigma’s international expansion strategy benefits from substantial financial support from Australian retail magnates. The company’s largest stakeholders include billionaire siblings Jack and Sam Gance, along with their longtime business associate Mario Verrochi — the three entrepreneurs who founded the Chemist Warehouse empire.
Verrochi currently holds a real-time net worth of $5.5 billion. Jack Gance’s wealth stands at $3.4 billion, while Sam Gance is valued at $3.2 billion, based on Forbes valuations.
Earlier this year in February 2025, Chemist Warehouse completed its merger with Sigma Healthcare, creating a combined pharmaceutical retail powerhouse valued at more than $22 billion. The merged organization now operates a network exceeding 950 retail locations spanning Australia, China, Dubai, Ireland, and New Zealand.
Implications of a Potential Boots Acquisition for Sigma
Acquiring Boots would represent far more than an incremental expansion. With a global network approaching 3,800 stores and franchise partnerships extending into the Middle East and Indonesia, this transaction would fundamentally transform Sigma’s international footprint.
The company has not publicly revealed any financial details regarding its potential offer, nor has it disclosed whether it plans to partner with financial institutions or investment groups to structure a transaction of this magnitude.
Wednesday’s negative stock price movement suggests market participants are approaching the potential deal with measured skepticism. A transaction valued above $10 billion would dwarf any previous acquisition undertaken by the company, and significant uncertainty surrounds whether negotiations will ultimately succeed.
Sigma has committed to providing market updates should any material developments emerge from the ongoing discussions.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
